—Jeffrey Rosenfeld, MD, PhD
Medical Director, The Center for Restorative Neurology
Loma Linda, CA
The image above is a patient portrayal and partial depiction of the MG-ADL scale, which assesses the impact of gMG on daily functions of 8 signs or symptoms that are typically affected in gMG. Each function is scored from 0-3: 0 represents normal function and 3 represents the loss of ability to perform that function. A total score can range from 0-24.
There are more options available for patients
The guidelines and conventional approach to treating gMG are evolving as new classes of treatment have been introduced.1,2
It’s time to challenge the status quo. Targeted therapies are no longer relegated to refractory patients, which could signal a different era in gMG.3*
Who could benefit from targeted treatment?
Several targeted treatments have been FDA approved, giving patients—even those with lower MG-ADL scores (5-11)—more options.4†
Patients with an MG-ADL score of 5 to 11 taking at least one form of traditional treatment have seen improvement with the addition of these FDA-approved targeted treatments.4
*Targeted therapies are treatments that target the underlying pathophysiological pathways of the disease.5
†Data was collected from 4 randomized, double-blind clinical trials (one phase 2 trial and three phase 3 trials) across 521 patients 18 years and older. Patients were on at least one standard-of-care therapy with MG-ADL baseline scores ranging from 5 to 11.6-9
gMG=generalized myasthenia gravis; MG-ADL Myasthenia Gravis Activities of Daily Living.
References: 1. Mantegazza R, Antozzi C. Front Neurol. 2020;11:981. doi:10.3389/fneur.2020.00981 2. Wiendl H et al. Ther Adv Neurol Disord. 2023;16:1-31. doi:10.1177/17562864231213240 3. Data on file, argenx US Inc. July 2024. 4. Saccà F et al. Eur J Neurol. 2023;30(12):3854-3867. doi:10.1111/ene.15872 5. Sánchez-Tejerina et al. J Clin Med. 2022;11(21):6394. doi:10.3390/jcm11216394 6. Bril V et al. Lancet Neurol. 2023;22(5):383-394. doi:10.1016/S1474-4422(23)00077-7 7. Howard JF Jr et al. JAMA Neurol. 2020;77(5):582-592. doi:10.1001/jamaneurol.2019.5125 8. Howard JF Jr et al. Lancet Neurol. 2021;20(7):526-536. doi:10.1016/S1474-4422(21)00159-9 9. Howard JF Jr et al. Lancet Neurol. 2017;16(12):976-986. doi:10.1016/S1474-4422(17)30369-1
For US audiences only. © 2024 argenx US-UNB-24-00044 V2 07/2024. All Rights Reserved.
We’ll be in touch!
An argenx representative will contact you soon, so keep an eye on your inbox.
Thank you for signing up!
We’re looking forward to sharing information about innovations in gMG with you. Keep an eye on your inbox for important updates on Raising the Bar in gMG.
gMG=generalized myasthenia gravis.